All Stories

Sanofi’s high hopes for $1.1B Kymab anti-inflammatory drug dented after phase 2 asthma failure

Sanofi’s blockbuster ambitions for amlitelimab hit a bump in the road this morning with the news that the highest dose of the anti-OX40-ligand monoclonal antibody missed the main goal of a phase 2 asthma study.

Apr 15, 2025 - 12:38
 0
Sanofi’s high hopes for $1.1B Kymab anti-inflammatory drug dented after phase 2 asthma failure
Sanofi’s blockbuster ambitions for amlitelimab hit a bump in the road this morning with the news that the highest dose of the anti-OX40-ligand monoclonal antibody missed the main goal of a phase 2 asthma study.
Read More

Tags:

Previous Article

Travel and tourism sees resilient M&A activity amid 5% dip in overall deal volum...

Next Article

B-21 Raider Expected to Arrive at Ellsworth AFB in ‘Mid 2020s’

Related Posts

Siemens Healthineers plans ‘mega depots’ to bolster US supply chain amid ‘geopolitical uncertainties’

Siemens Healthineers plans ‘mega depots’ to bolster US ...

Feb 19, 2025  0

Concentra swoops in to buy struggling Allakos, softening the blow of other denied buyout attempts

Concentra swoops in to buy struggling Allakos, softenin...

Apr 2, 2025  0

Mineralys’ stock jumps as hypertension drug posts double clinical wins

Mineralys’ stock jumps as hypertension drug posts doubl...

Mar 10, 2025  0